Kyowa Hakko Kogyo Co., Ltd.

Cephalon, Inc.

Kyowa Hakko Kogyo Kabushiki Kaisha

Other

Kyowa Hakko Kogyo

Kyowa Hakko Kabushiki Kaisha

Yuzuru Matsuda

Isao Kawamoto

Takeo Tanaka

Chikara Murakata

Hiromitsu Saito

Katsuhiko Ando

James C Kauer

Michael E Lewis

Mayumi Yoshida

Nicola T Neff

Marcie A Glicksman

Jill M Roberts-Lewis

Eiji Tsukuda

Fumihiko Kanai

Masami Kaneko

Yoshikazu Morishita

Kenji Shibata

Motoo Yamasaki

Keiichi Yano

Hiroshi Kase

Kunikatsu Shirahata

Kazuo Yamaguchi

Toshiyuki Suzawa

Shigeto Kitamura

Shigeru Chiba

Hidemasa Kondo

Tatsuhiro Ogawa

Mika Makino

Toshihide Ikemura

Fumito Koizumi

Chieko Bando

Hiroshi Sano

Yutaka Saitoh

Koji Yamada

Tsutomu Agatsuma

Kozo Asano

Yutaka Saito

Mitsuru Takahashi

Hirofumi Nakano

Kazuhiro Kubo

Junichi Shimada

Keiko Ochiai

Katsuichi Shuto

Fusao Tomita

Takao Iida

Keiichi Takahashi

Hideaki Kusaka

Satoshi Nakanishi

Emi Arakawa

Youichi Uosaki

Tomoyasu Sato

Yoshihisa Ohta

Hiroki Ishiguro

Noriaki Hirayama

Junichi Ikeda

Nobuo Nakamura

Shuji Okubo

Tohru Yasuzawa

Kazuhide Hasegawa

Kotaro Takasaki

Hiroshi Yano

Kazuyuki Iwahashi

Katsuhito Takahashi

Shoji Oda

Michihiro Sugahara

Haruo Ishiyama

Miho Suda

Tomoyuki Sano

Mika Nozawa

Shinichiro Toki

Endothelin-antagonizing peptide

The present invention relates to recombinant DNA comprising DNA coding for smooth-muscle-type myosin heavy chain SM1 isoform protein inserted into vector DNA, a microorganism carrying the recombinant DNA, and an agent for treatment of arteriosclerosis comprising the recombinant DNA. The recombinant DNA of the present invention can be used effectively as an agent for gene therapy of restenosis after PTCA treatment.

RECOMBINANT DNA COMPRISING DNA CODING FOR MYOSIN HEAVY CHAIN SM1 ISO-FORM PROTEIN INSERTED INTO VECTOR DNA MICROORGANISM CARRYING THE RECOMBINANT DNA, AND AN AGENT FOR TREATMENT OF ARTERIOSCLEROSIS COMPRISING THE RECOMBINANT DNA

Remedies for diabetes

The invention relates to biologically pure cultures of Streptomyces sp. RE-701 (FERM BP-3624) and Streptomyces sp. RE-629 (FERM BP-4126) that produce endothelin antagonistic peptides.

Strains of streptomyces producing endothelin antagonistic peptides

Physiologically active substance EI-2128-1

Provided is an Interleukin-1 production inhibiting compound represented by formula (I) ##STR1## wherein R denotes 4-methyl-1-pentenyl, 5-methyl-1,3-heptadienyl or 1-methylpentanyl.

Interleukin-1 production inhibiting compound

The invention features novel derivatives of K-252a, as well as novel bis-N-substituted derivatives of staurosporine. The invention also features a method for treating diseased neuronal cells involving the administration of either the novel staurosporine derivatives or specified functional derivatives of K-252a.

Protein kinase inhibitors for treatment of neurological disorders

Protein kinase inhibitors for treatmen of neurological disorders

The present invention relates to EI-1941 compounds having interleukin-1 production inhibitory activity which are represented by the formula: ##STR1## wherein either of R.sup.1 and R.sup.2 is hydrogen and the other is hydroxy, or R.sup.1 and R.sup.2 together represent oxygen; and R.sup.3 is hydroxy and R.sup.4 is hydrogen, or R.sup.3 and R.sup.4 together represent --0--.

Physiologically active EI-1941 compounds

Peptides represented by the following formula (I): ##STR1## wherein A represents Asn or Asp; B represents His or Lys; and E represents Ala or Ser;

K-252a derivatives for treatment of neurological disorders

The invention features novel derivatives of K-252a, as well as novel bis-N-substituted derivatives of staurosporine. Also, a method for treating diseased neuronal cells involving the administration of either the novel staurosporine derivatives or specified functional derivatives of K-252a.

Selected protein kinase inhibitors for the treatment of neurological

Compounds comprising a linear .beta.1.fwdarw.6 glucan esterified by caproic acid, the number of D-glucose residues being from 7 to 40 and the number of caproic acid residues being from 2 to 30, may be be obtained by fermentation of a microorganism of the genus Aureobasidium. These compounds are designated HS-142-1. Preferred microorganism is Aureobasidium pullulans var. melanigenum KAC-2383 (FERM-BP 2407). The compounds of the present invention exhibit excellent antagonistic activity to ANP and are capable of inhibiting the bonding of ANP to ANP receptors.

HS-142-1 compounds

A compound of formula (I): ##STR1## wherein R.sub.1 represents hydrogen, hydroxy or acetoxy and R.sub.2 represents hydroxy or acetoxy.

Bioxanthracene derivatives

Growing community of inventors

Koganei, Japan

Yuzuru Matsuda